Minneapolis, U.S., and Brisbane, Australia, January 21, 2026 — Anteris Technologies Global Corp. announced the pricing of a $200 million public offering to support the next phase of its clinical and manufacturing expansion, including execution of its global PARADIGM pivotal trial evaluating the DurAVR® Transcatheter Heart Valve (THV) in patients with severe aortic stenosis.
Science Significance
Scientifically, the funding underpins continued development of next-generation transcatheter heart valve technology designed to more closely replicate native human valve function. Anteris’ DurAVR® THV is positioned as the first biomimetic transcatheter valve, engineered to restore physiologic blood flow patterns rather than simply replacing valve function. Central to this innovation is the company’s ADAPT® anti-calcification tissue, a single-piece molded material designed to enhance durability and reduce structural degeneration. By supporting ongoing research and iterative design optimization, the capital raise reinforces Anteris’ ability to advance science-driven MedTech innovation in a therapeutic area with growing global demand.
Regulatory Significance
From a regulatory perspective, the announcement is closely tied to active, GCP-aligned clinical development. Proceeds will fund ongoing recruitment and execution of the PARADIGM global pivotal trial, a key step toward future regulatory submissions in major markets. The DurAVR® THV system incorporates components, including FDA-cleared ADAPT® tissue, that already meet stringent regulatory standards, while the pivotal study will generate the safety and effectiveness data required for device approval pathways. In parallel, expanded manufacturing investment supports quality system compliance, scale-up validation, and supply chain robustness, all critical for successful regulatory review and commercialization.
Business Significance
Advertisement
From a business standpoint, the $200 million offering represents a transformational capital event for Anteris, significantly extending its financial runway and de-risking execution of late-stage development. The participation of Medtronic through a private placement further validates the strategic relevance of Anteris’ technology within the global structural heart market. The funds will enable the company to scale manufacturing capabilities, invest in its subsidiary v2vmedtech, and maintain operational flexibility as clinical milestones are achieved. For the MedTech sector, the transaction highlights continued investor confidence in capital-intensive, late-stage device innovation with clear clinical differentiation.
Patients’ Significance
For patients with severe aortic stenosis, a life-threatening condition characterized by narrowing of the aortic valve, the advancement of the DurAVR® THV holds meaningful potential. Existing transcatheter valves have transformed care for high-risk patients, but durability and long-term hemodynamic performance remain critical challenges. By aiming to replicate normal valve biomechanics and blood flow, the DurAVR® THV could improve long-term outcomes, reduce complications, and expand treatment options for a broader patient population. Continued investment ensures that patients enrolled in the PARADIGM Trial and future studies have access to rigorously evaluated, next-generation devices.
Policy Significance
At the policy level, the announcement reflects broader healthcare priorities focused on innovation in cardiovascular care, an area with significant public health burden. Aortic stenosis prevalence is increasing with aging populations, placing pressure on healthcare systems worldwide. Investments that support clinically validated, durable device solutions align with policy goals to reduce repeat interventions, hospitalizations, and long-term costs. Additionally, the cross-border nature of Anteris’ operations and trials underscores the importance of harmonized regulatory frameworks that enable global clinical development and timely patient access to advanced MedTech solutions.
Overall, Anteris Technologies’ $200 million public offering, complemented by strategic investment from Medtronic, marks a pivotal moment in the company’s evolution as a late-stage structural heart innovator. By strengthening its balance sheet and accelerating the PARADIGM pivotal trial, Anteris is positioning the DurAVR® THV for potential regulatory advancement and future commercialization. For the cGxP.wire audience, the announcement illustrates how capital strategy, clinical execution, regulatory readiness, and manufacturing scale converge to drive progress in regulated medical device development, ultimately shaping the future of cardiovascular care.
Source: Anteris Technologies Global Corp. press release
